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Needs for an Expanded 
Ontology-Based Classification 
of Adverse Drug Reactions and 
Related Mechanisms
PE Zhichkin1, BD Athey2, MI Avigan3 and DR Abernethy1
The growing significance of bioinformatics and systems biology in 
drug safety research requires a system of adverse-event classification 
that goes beyond a simple vocabulary. This opinion piece outlines 
the need for development of an ontology-based framework of 
describing adverse drug reactions (aDrs) and describes the potential 
applications for such a framework.
The standard classification for ADRs is 
the Medical Dictionary for Regulatory 
Activities (MedDRA) terminology, 
developed under the auspices of the 
International Conference on Harmoni-
sation. Among other users, regulatory 
authorities worldwide, including the US 
Food and Drug Administration, employ 
it in the evaluation of clinical trials and 
postmarketing surveillance reports. 
With more than 90,000 terms structured 
in five levels of hierarchy, the MedDRA 
provides both granularity of detail and 
the higher level descriptions by group-
ing adverse effects into classes.1
This has served the public health 
well; however, we believe that, to con-
tinue to advance the science of drug 
safety, ADR classifications must evolve 
beyond relatively simple vocabularies 
and toward being the knowledge frame-
work for a systematic organization of 
all ADR-related data and information. 
This capability promises to enable new 
discoveries, inform researchers and 
regulators, and create new biosurveil-
lance capabilities.
Our proposed ontology-integra-
tion approach offers a model of such 
organization and is consistent with the 
approach recommended in the recent 
National Research Council report on 
the new taxonomy of disease.2 Dis-
tinctive characteristics of an ontology 
are logical consistency of definitions 
of classes in the biological and clinical 
hierarchies and rigorous formal rules 
of organization, in which links between 
terms are usually specified using OWL 
Web Ontology Language and the Pro-
tégé authoring tool (http://protege.stan-
ford.edu). A key underlying principle is 
that the terms composing an ontology 
have properties (or attributes) defined 
through, or compatible with, other 
ontologies from other related areas of 
knowledge.3 This enables the creation 
of an overlapping network of terms and 
definitions between different specialized 
areas that would considerably simplify 
computational treatment of complex 
multilevel interdisciplinary problems. 
The prime example of such a unifying 
ontology is Gene Ontology, which has 
become indispensable in many areas 
of bioinformatics.4
Similarly, an ontological organiza-
tion of the ADR-related knowledge can 
lead to the creation of a sharable infra-
structure enabling and expanding the 
applications of bioinformatics, next-
generation sequencing, the “-omics,” 
and systems biology, to drug safety. As 
systems biology extends its reach to ena-
ble predicting and explaining of ADRs,5 
the need for an ADR ontology becomes 
apparent. Particularly useful will be an 
ontology providing the framework for 
linking ADRs with biological mecha-
nisms and function, establishing cor-
relations between them, and allowing 
statistically meaningful inference from 
one to the other.
Considering the established role of 
the MedDRA, the adverse reactions 
and mechanisms (ARM) ontology will 
be founded on MedDRA terms and 
consistent with MedDRA general clas-
sifications whenever possible. Some of 
the MedDRA terms (e.g., the codes for 
medical procedures and for medical/
social/family background and circum-
stances) can be omitted or de-empha-
sized. Concentrating on medical terms 
that are used in clinical trials and medi-
cal practice will reduce the number of 
terms and allow for adding new attrib-
utes and expanding the ontology.
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drug mechanism of action, thus laying 
one of the foundational elements for the 
advancement of predictive toxicology.
The ARM ontology is likely to fur-
ther serve as a template for building 
classifications in adjacent areas of bio-
medical science. For example, drugs 
can be classified based on the classes of 
ADRs they cause; genes and biological 
mechanisms can be grouped based on 
the classes of ADRs for which they are 
responsible. As such classifications are 
being developed, they will make more 
apparent the relationships between 
drugs, their targets, biological pathways 
they alter, and ADRs they cause, making 
the details of these interactions visible 
to various communities of users from 
basic researchers to regulators.
A variety of models, from simple path 
tracing to Bayesian networks, can be 
built on top of this foundation. If such a 
network of drugs, biological pathways, 
and corresponding ADRs is further 
linked to patients’ genetic and genomic 
profiles and pretreatment phenotype 
data, a future goal will be to quantify 
the contributions of drug molecular tar-
gets and an individual patient’s charac-
teristics to the likelihood of an ADR in 
individuals or patient subgroups.
We believe the development of the 
ARM ontology with an integrated bio-
systems approach will prove invaluable 
in the analysis of a variety of important 
regulatory questions. Such a capability, 
as it is developed and gains acceptance, 
may also eventually augment current 
methods used in the identification and 
evaluation of drug-related risk. This 
concept has yet to be rigorously and 
formally tested, and its areas of appli-
cability and limitations have to be more 
fully defined. Moreover, the drawing of 
conclusions from purely bioinformat-
ics-based approaches, without a careful 
understanding and analysis of the range 
and quality of individual ADR cases, 
may be fraught with hazard.
It is clear that ontology-based search 
strategies will need to be complemented 
by an analysis of cases for appropriate 
case inclusion or exclusion, and would 
employ uniformly accepted case defi-
nitions. This is particularly important 
in the assessment of ADRs that are 
A prototype of such query expansions 
can be seen in the way PubMed, by 
default, expands simple searches by 
using related MeSH synonyms.
As with any ontology, significant util-
ity of the ARM ontology will stem from 
its integration with other medical classi-
fication systems so that the data gathered 
from different databases can be readily 
imported and seamlessly used together. 
The ARM ontology terms will need to 
map to the standard medical diagnostic 
terms (International Classification of 
Diseases, ICD), to terms used in litera-
ture searches (MeSH), and to electronic 
medical records using the Systematized 
Nomenclature of Medicine—Clinical 
Terms (SNOMED-CT). The mapping 
of MedDRA to ICD and SNOMED-CT 
performed at the National Center for 
Biomedical Ontology Bioportal (http://
bioportal.bioontology.org/mappings) 
considerably simplifies this task.
Carrying out this alignment of classi-
fications will require employing another 
feature of ontologies: their ability to 
store additional information in the 
term-to-term links between ontolo-
gies. These interontological links are 
specified by assigning terms from one 
ontology to be additional attributes of a 
term in the second ontology. The most 
obvious attributes to assign to an ADR 
term are the name of drugs causing a 
particular ADR, ADR frequencies for 
each drug and the molecular mecha-
nisms responsible for the ADR. In this 
manner, a system integrating relevant 
fields can be designed around the evolv-
ing ARM ontology.
As noted above, the connections 
between terms in the ARM ontology 
will be encoded using OWL. This is very 
important for consistency and interop-
erability, as most other ontologies of 
biological pathways and mechanisms 
such as Gene Ontology also use OWL 
or a compatible language. This should 
allow structured computational-based 
reasoning services that can be pro-
grammed, not only about ADRs and 
their links with each other but also 
about ADR connections with outside 
terms. The reasoning software may 
ultimately be capable of semiautomati-
cally inferring the set of ADRs from the 
To support clear logical links to bio-
logical mechanisms, the hierarchies in 
the ARM ontology have to be rooted in 
the underlying biology and physiology 
of adverse events. This may cause some 
classes and groupings of ARM ontology 
to differ from those in the MedDRA 
because the MedDRA uses anatomy 
as its primary organizing principle.1 
Future research and development can 
extend this to physiology.
In addition to providing standard-
ized terms and classification hierarchy, 
an important function of an ontology 
is to supply the consensus definitions 
of the terms, leading to a meaningful 
set of Common Data Elements (CDEs). 
These standardized terms and defini-
tions will be based on openly available 
medical dictionaries. For example, many 
ADR definitions can be automatically 
imported from the National Library of 
Medicine (NLM) Unified Medical Lan-
guage System (UMLS) and its Medical 
Subject Heading vocabulary (MeSH), 
provided in a machine-readable format 
by the NLM. The decreased ambiguity 
of classification will reduce misclas-
sification errors and should improve 
the precision of the ARM ontology-
based applications.
It is a standard pharmacovigilance 
practice to group different terms related 
to the same pathological phenomenon 
independently from MedDRA hierar-
chies. These MedDRA terms groupings, 
called Standardized Medical Queries 
(SMQs), are routinely used for mining 
the ADR databases in search of events 
marked by medical conditions with 
multiple possible manifestations.1 The 
ARM ontology, being biologically based, 
will naturally incorporate many of the 
groupings defined by SMQs and is likely 
to make the construction of future SMQs 
a more logical and streamlined pro-
cess. Perhaps more importantly, in the 
future it is expected that the ARM would 
enable more powerful computationally 
adaptive ad hoc querying strategies.
Another potential application of ARM 
ontology is an automatic expansion of 
ADR searches to progressively broader 
concepts, with the desired level of com-
monality defined by the user by specify-
ing the level of hierarchy for the search. 
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clinically serious, because these events 
are most likely to have the strongest 
impact in gauging overall drug-related 
risk. Some essential information about 
this risk can only be gathered from 
an assessment of single ADR cases to 
characterize the range of clinical and 
laboratory findings on presentation, the 
clinical course and complications that 
may ensue, and the statistical likelihood 
of drug-induced causality.
In conclusion, with the advances 
in the sciences of bioinformatics and 
systems analysis in medicine, the 
foundation for the ontology-enabled 
integration of drug safety with molec-
ular biology data is quickly becoming 
possible. This is needed to keep drug 
safety science abreast of the evolving 
science in the wider biomedical com-
munity. We expect such a foundation 
built on the principles of ontology inte-
gration and services extension to ena-
ble multiple applications, ranging from 
more powerful search strategies in post-
marketing safety to ADR predictions.
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Healthy Volunteer Registries and 
Ethical Research Principles
EA Kupetsky-Rincon1 and WK Kraft1
The dual enrolling of phase i volunteers is a potential risk to subjects. 
it can also distort study results, threaten study validity, and possibly 
cause harm to future patients. existing subject registries differ in 
structure, funding, and governance. although the choice of the ideal 
system is driven by the scope of the risk and the funding mechanism, 
and is ultimately a value judgment of freedom versus paternalism, 
none of the registries significantly impinges on the tenets of ethically 
based research.
The Belmont report, issued in 1978 by the 
National Commission for the Protection 
of Human Subjects of Biomedical and 
Behavioral Research, identified the key 
pillars of ethical research to be justice, 
autonomy, and beneficence. A key prin-
ciple is that human-subject research has 
a responsibility to minimize harm and 
maximize benefit for participants as long 
as there is acceptable equipoise. There 
is, however, no absolute requirement of 
potential benefit of participation, even 
for those with disease. For example, 
although oncologists and patients par-
ticipate in phase I oncology trials with a 
primary hope for therapeutic response, 
drug efficacy is not necessarily an imme-
diate goal of these studies. The lack of 
understanding of this distinction by 
patients has been well described. Other 
study designs, such as those of nonin-
feriority or comparative effectiveness, 
do not provide patients with a direct 
benefit of participation beyond access 
to care and/or financial compensation. 
Healthy-volunteer studies entail risk, 
with no potential for therapeutic benefit 
to participants. The lack of any potential 
health benefit outside of an evaluation 
of health status has often led to height-
ened institutional review board scrutiny 
for phase I studies. The focus of regula-
tion in healthy-volunteer clinical trials 
is typically the short-term protection of 
subjects from harm directly related to 
study procedures. Outside of cumulative 
limits on radiation exposure, the role of 
the subject outside of an individual trial 
is generally not considered. The National 
Institutes of Health (NIH) and the US 
Food and Drug Administration (FDA) do 
not strictly limit the number of studies 
in which a volunteer can participate. It is 
merely suggested that subjects not enroll 
in consecutive studies without adequate 
time for washout of drug or intervention 
based on the biology of the system. How-
ever, there have recently been concerns 
about the potential for phase I volunteer 
participants to enroll in multiple clinical 
trials concurrently, with calls for a man-
datory registry to track subjects.1
Motivations for healthy-volunteer 
participants in clinical research can be 
altruistic, especially for disease-specific 
activists or those with afflicted family 
members. Generally, however, the prime 
motivation for most phase I trial enroll-
ees who lack an underlying disease is in 
the financial compensation for partici-
pation.2,3 Pursuit of compensation can 
incentivize subjects to enroll in multiple 
studies, despite the potential for per-
sonal injury, or risk of discovery and loss 
1Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, 
Pennsylvania, USA. Correspondence: WK Kraft (Walter.Kraft@jefferson.edu)
doi:10.1038/clpt.2012.32
